CEBPB

Across TCGA pan-cancer cohorts, CEBPB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CEBPB data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CEBPB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CEBPB expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where CEBPB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.706	0.967	<.001	88	view →
PDAC	DFS	Median	II,III,IV	0.289	0.492	<.001	68	view →
HNSC	OS	Tertile	All	0.947	0.166	.010	34	view →
LUAD	OS	Tertile	II,III,IV	0.212	0.754	.002	31	view →
COAD	DFS	Median	All	0.865	1.000	.015	18	view →
GBM	OS	Median	All	0.393	0.676	.001	16	view →
LSCC	OS	Median	III,IV	0.996	0.712	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CEBPB–CCRCC (OS)

Open the CCRCC breakdown →